CF PharmTech repurchases 8,500 H-shares; treasury stock rises to 0.71 million

Bulletin Express05-11

CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80 and HKD 22.00, translating to a volume-weighted average of HKD 21.93 and a total outlay of approximately HKD 0.19 million.

The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0028% to 301.52 million shares. Concurrently, the treasury-share balance increased from 0.70 million to 0.71 million, while the total number of issued shares remained unchanged at 302.22 million.

The buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, CF PharmTech has repurchased 707,500 shares under this mandate, utilising 0.23% of the authorised limit.

In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 June 2026. Management confirmed that the repurchase complied with all applicable regulations and that all required approvals and filings are in place.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169487372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169487372","market":"us","top_or_hot":-1,"title":"CF PharmTech repurchases 8,500 H-shares; treasury stock rises to 0.71 million","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80 and HKD 22.00, translating to a volume-weighted average of HKD 21.93 and a total outlay of approximately HKD 0.19 million.</p>\n<p>The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0028% to 301.52 million shares. Concurrently, the treasury-share balance increased from 0.70 million to 0.71 million, while the total number of issued shares remained unchanged at 302.22 million.</p>\n<p>The buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, CF PharmTech has repurchased 707,500 shares under this mandate, utilising 0.23% of the authorised limit.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 June 2026. Management confirmed that the repurchase complied with all applicable regulations and that all required approvals and filings are in place.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 8,500 H-shares; treasury stock rises to 0.71 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 8,500 H-shares; treasury stock rises to 0.71 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-11 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80 and HKD 22.00, translating to a volume-weighted average of HKD 21.93 and a total outlay of approximately HKD 0.19 million.</p>\n<p>The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0028% to 301.52 million shares. Concurrently, the treasury-share balance increased from 0.70 million to 0.71 million, while the total number of issued shares remained unchanged at 302.22 million.</p>\n<p>The buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, CF PharmTech has repurchased 707,500 shares under this mandate, utilising 0.23% of the authorised limit.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 June 2026. Management confirmed that the repurchase complied with all applicable regulations and that all required approvals and filings are in place.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1169487372","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169487372","pubTimestamp":1778502169,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购8,500股H股；库存股升至71万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80 and HKD 22.00, translating to a volume-weighted average of HKD 21.93 and a total outlay of approximately HKD 0.19 million.\nThe transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0028% to 301.52 million shares. Concurrently, the treasury-share balance increased from 0.70 million to 0.71 million, while the total number of issued shares remained unchanged at 302.22 million.\nThe buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, CF PharmTech has repurchased 707,500 shares under this mandate, utilising 0.23% of the authorised limit.\nIn line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 June 2026. Management confirmed that the repurchase complied with all applicable regulations and that all required approvals and filings are in place.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169487372","isCrawlerRequest":true}